Form 8-K - Current report:
SEC Accession No. 0001193125-21-359144
Filing Date
2021-12-16
Accepted
2021-12-16 16:04:34
Documents
14
Period of Report
2021-12-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d246572d8k.htm   iXBRL 8-K 46764
2 EX-3.1 d246572dex31.htm EX-3.1 200175
  Complete submission text file 0001193125-21-359144.txt   512680

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lly-20211213.xsd EX-101.SCH 6215
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lly-20211213_def.xml EX-101.DEF 17413
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lly-20211213_lab.xml EX-101.LAB 30147
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lly-20211213_pre.xml EX-101.PRE 19031
7 EXTRACTED XBRL INSTANCE DOCUMENT d246572d8k_htm.xml XML 16147
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Filer) CIK: 0000059478 (see all company filings)

EIN.: 350470950 | State of Incorp.: IN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06351 | Film No.: 211497829
SIC: 2834 Pharmaceutical Preparations